Ultrafast 30-min infusion of a rituximab biosimilar (Truxima).

ABSTRACT: In this clinical trial, we demonstrate that ultrarapid fast infusion of rituximab (Truxima) in 30 min with oral premedication is feasible and secure for patients, and reduce the day-care hospital stays.

SUBMITTER: Perez-Persona E 

PROVIDER: S-EPMC10660389 | biostudies-literature | 2023 Nov

REPOSITORIES: biostudies-literature